Day: February 28, 2024

U.GG League of Legends Desktop Application Monetized 8x Better than Website in Q4 2023 LOS ANGELES, Feb. 28, 2024 (GLOBE NEWSWIRE) — Enthusiast Gaming Holdings Inc. (“Enthusiast Gaming” or the “Company”) (TSX: EGLX), the leading gaming and media company in North America, is pleased to announce that its data-driven and insights platform, U.GG, has achieved over 2.1 million downloads of its League of Legends desktop applications, including over 575,000 downloads of its proprietary application since June 2023. This milestone highlights the continued progress of the Company’s strategic goal to convert the 10 million monthly average users of U.GG’s website into users of its proprietary desktop application where it benefits from significantly improved monetization, with Q4 2023 monetization per user showing an 8x improvement on the desktop...

Enrollment in dose escalation and backfill cohorts continuing in Phase 1 clinical trial of XMT-1660; expect to initiate tumor-specific expansion cohorts in the second quarter of 2024 and announce initial clinical data in mid-2024 Phase 1 clinical trial of XMT-2056 restarting; plan to advance dose escalation in 2024 Continue to expect capital resources will support current operating plan commitments into 2026 Conference call today at 8:00 a.m. ETCAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) — Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and reported financial results for the fourth quarter and full year ended December...

MONTREAL, Feb. 28, 2024 (GLOBE NEWSWIRE) — Stella-Jones Inc. (TSX:SJ).    OPEN TO: Investors, analysts and all interested parties   DATE: Thursday, February 29, 2024   TIME: 10:00 AM Eastern Standard Time   LIVE WEBCAST: https://web.lumiagm.com/440096911   CALL: 1-866-518-4114   THE PRESS RELEASE WILL BE PUBLISHED BEFORE MARKET OPENS THE DAY OF THE CONFERENCE CALL THROUGH GLOBENEWSWIRE. Please log on or dial in 15 minutes before the conference begins. If you are unable to attend at this time, you may access a web recording of the meeting at the following link: https://web.lumiagm.com/440096911. This recording will be available on Thursday, February 29, 2024 as of 1:00 PM EST until 11:59 PM EST on Thursday March 7, 2024. MEDIA WISHING TO QUOTE AN ANALYST SHOULD CONTACT THE ANALYST PERSONALLY FOR...

NEW YORK and SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) — Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancer, today announced that Zentalis management will participate in several upcoming investor conferences:TD Cowen 43rd Annual Health Care Conference Location: Boston, MA Event: Gynecological Cancers Corporate Panel Discussion Date and Time: March 5 at 10:30 a.m. ETLeerink Partners Global Biopharma Conference Location: Miami, FL Event: Fireside discussion Date and Time: March 11 at 3:20 p.m. ETJefferies Biotech on the Bay Summit Location: Miami, FL Event: Investor meetings only Date: March 12Access to a live webcast of this event, as well as an archived...

Fourth Quarter and Full Year 2023 Overview (all comparisons are made to the corresponding prior year fourth quarter or prior year, as applicable):Net sales decreased 3.6% to $337.2 million in the quarter. Full year net sales increased 5.0% to $1.3 billion. Gross margin of 26.4% increased 610 basis points in the quarter. Full year gross margin of 24.7% increased 400 basis points. Diluted EPS of $0.65 compared to $(0.04) in the quarter; Adjusted EPS of $0.90 compared to $0.34 in the quarter. Full year diluted EPS of $1.47 compared to $0.00; full year Adjusted EPS of $2.67 compared to $1.23. Backlog of $569.8 million as of December 31, 2023 continued to normalize from $969.0 million peak at September 30, 2022. Implied orders increased 27.6% sequentially from the third quarter.CHATTANOOGA, Tenn., Feb. 28, 2024 (GLOBE NEWSWIRE) —...

TORONTO and BROSSARD, Québec, Feb. 28, 2024 (GLOBE NEWSWIRE) — Bitfarms Ltd. (NASDAQ/TSX: BITF), a global vertically integrated Bitcoin mining company, will report its fourth quarter and full year 2023 financial results on Thursday, March 7, 2024 before the market opens. Management will host a conference call on the same day at 8:00am EST. A presentation of the Q4 2023 results will be accessible before the call on the Investor website and can be accessed here. Participants are asked to pre-register for the event through the following link:Q4 2023 Conference Call. Please note that registered participants will receive their dial-in number upon registration and will dial directly into the call without delay. Those unable to pre-register may dial in by calling: 1-866-777-2509 (domestic), or 1-412-317-5413 (international), and should...

Fourth quarter and full year 2023 BRIUMVI U.S. net revenue of approximately $40 million and $89 million, respectively Conference call to be held today, February 28, 2024, at 8:30 AM ET    NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) —  TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the fourth quarter and year ended December 31, 2023, along with recent company developments. Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, stated, “2023 was an exciting year of execution for TG, which we believe has set the stage for a successful 2024. The BRIUMVI launch exceeded our expectations, and we ended the year with approximately $89 million in U.S. net revenue and provided a BRIUMVI U.S. net revenue target of $220 – $260 million for 2024. Further...

WATERTOWN, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events:TD Cowen 44th Annual Healthcare Conference in Boston, MA on March 6 at 12:50 p.m. ET; Leerink Partners Global Biopharma Conference in Miami, FL on March 12 at 3:40 p.m. ET; Jefferies Biotech on the Bay Summit in Miami, FL on March 13, the Company will host one-on-one meetings only; and H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference on March 28 at 10:30 a.m. ET.Live webcasts of the presentations will be available under “News and Events” in the Investors section...

Full Year Net Sales Increased 15% to $494 million Driven by Vita Coco Coconut Water Growth of 14% Full Year Net Income of $47 million and Full Year Non-GAAP Adjusted EBITDA1 of $68 million For Fiscal Year 2024, Expect Net Revenue between $495–$505 million and Adjusted EBITDA2 between $74–$78 million NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) — The Vita Coco Company, Inc. (NASDAQ:COCO) (“Vita Coco” or “the Company”), a leading high-growth platform of better-for-you beverage brands, today announced financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter 2023 Highlights Compared to Prior YearNet sales grew 15% to $106 million, driven by strong 8% net sales growth and 3% volume growth of Vita Coco Coconut Water. Gross profit was $40 million, or 37% of net sales, an increase of $17...